Fenimide

Fenimide

SCHEMBL121573

CCC1C(=O)NC(=O)C1(C)c1ccccc1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 3/20 0.42
▸ MMP9 P14780 3/20 0.42
▸ TSHR P16473 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ APEX1 P27695 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADRB3 P13945 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ HTR7 P34969 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22623692 0.69 TSHR (0.41) MMP2MMP9TSHRMEN1KMT2A
SCHEMBL22623637 0.67 KMT2A (0.41) MMP2MMP9TSHRMEN1KMT2A
SCHEMBL5924241 0.64 ALDH1A1 (0.42) MMP2MMP9TSHRMEN1KMT2A
SCHEMBL22898655 0.63 ADRA2A (0.44) TSHRMEN1KMT2AADRA2ACYP2C19
SCHEMBL22623635 0.63 MMP2 (0.40) MMP2MMP9TSHRMEN1KMT2A
SCHEMBL11840089 0.61 CYP19A1 (0.52) TSHRMEN1KMT2ACYP1A2POLB
SCHEMBL5924439 0.60 CYP2C19 (0.50) TSHRMEN1KMT2ACYP1A2POLB
SCHEMBL19645717 0.60 MEN1 (0.42) MEN1KMT2ALMNAMAPT
Phenobarbital SCHEMBL16583 0.59 MMP2 (0.80) MMP2MMP9TSHRMEN1KMT2A
Phenobarbital SCHEMBL2592325 0.59 MMP2 (0.80) MMP2MMP9TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 — — EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
US-20090220611-A1 Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same FLAMEL TECHNOLOGIES, S.A. (FR) 2009-09-03 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
EP-1931320-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME Flamel Technologies (FR) 2008-06-18 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
WO-2007036671-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME FLAMEL TECHNOLOGIES (FR) 2007-04-05 — — WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
EP-1044023-B1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA LUITPOLD PHARM INC (US) 2005-05-25 — — EP claimed
US-6197764-B1 COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS PROTARGA, INC. 2001-03-06 — — US claimed
EP-1044023-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA Protarga Inc. (US) 2000-10-18 — — EP claimed
US-5955459-A Fatty acid-antipsychotic compositions and uses thereof NEUROMEDICA, INC. (US) 1999-09-21 — — US claimed
WO-1999026661-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA PROTARGA INC. (US) 1999-06-03 — — WO claimed
EP-0417057-A2 Heterocyclic thiol-based sulfenimide compounds and rubber compositions containing them MONSANTO COMPANY (US) 1991-03-13 — — EP claimed
Send feedback